Second drug spending report predicts double-digit increases coming

Eric Palmer In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes ...

AbbVie angles for hep C spotlight as Merck shoulders to the front

Damian Garde While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data ...

Chimerix CEO Moch steps down after compassionate-use controversy

Alok Saboo FierceBiotech News

EU takes up testosterone drug review on cardio worries

Carly Helfand The FDA has been reviewing testosterone drugs since January of this year on concerns over their cardiovascular safety. Now, its across-the-pond counterpart is following ...

Intercept grabs the spotlight at EASL, builds case for lead drug OCA

John Carroll Investigators for Intercept Pharmaceuticals spelled out the impact of its lead therapy on rare cases of a liver disease called primary biliary cirrhosis (PBC), fleshing ...

Daiichi Sankyo lays out road map for Ranbaxy deal with Sun

Eric Palmer Daiichi Sankyo today released its road map for the $ 3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some ...

Biotech stocks tumble on phantom terror as analysts struggle to explain

Damian Garde The Nasdaq biotech index slumped another 5.6% on Thursday, and it's apparently anyone's guess as to why. FierceBiotech News

Vivus needs more than boardroom shuffling to keep up with Arena’s Belviq

Carly Helfand One pre-First Manhattan Co.-settlement Vivus director standing for re-election at the company's annual meeting, that is. The Mountain View, CA-based drugmaker announced ...

National Cancer Institute investigating trial outliers to resurrect ‘failed’ drugs

Emily Mullin After sifting through 10 years' worth of clinical trial data, NCI's Cancer Diagnosis Program says the program has identified about 100 "exceptional responders": ...

Biotech stock tumble stumps analysts

Carly Helfand Nobody quite knows why the Nasdaq biotech index sank another 5.6% on Thursday. Analysts do know that the drop came the day after the index jumped 4.1%, also inexplicably, ...

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

Tracy Staton With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, ...

Bristol-Myers jockeys for promising position in hep C drug race

John Carroll FierceBiotech News
Page 5 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS